Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;16(6):42.
doi: 10.1007/s11934-015-0507-9.

The role of MRI in active surveillance for prostate cancer

Michele Fascelli  1 , Arvin K George, Thomas Frye, Baris Turkbey, Peter L Choyke, Peter A Pinto
Affiliations
Review

The role of MRI in active surveillance for prostate cancer

Michele Fascelli et al. Curr Urol Rep. 2015 Jun.

Abstract

Approximately one in seven American men will be diagnosed with prostate cancer during his lifetime, and at least 50% of newly diagnosed patients will present with low-risk disease. In the last decade, the decision-making paradigm for management has shifted due to high rates of disease detection and overtreatment, attributed to prostate-specific antigen screening, with more men deferring definitive treatment for active surveillance. The advent of multiparametric magnetic resonance imaging (MP-MRI) and MRI/ transrectal ultrasound-guided fusion-guided prostate biopsy has refined the process of diagnosis, identifying patients with clinically-significant cancer and larger disease burden who would most likely benefit from intervention. In parallel, the utilization of MP-MRI in the surveillance of low-grade, low-volume disease is on the rise, reflecting support in a growing body of literature. The aim of this review is to appraise and summarize the data evaluating the role of magnetic resonance imaging in active surveillance for prostate cancer.

PubMed Disclaimer

References

    1. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(11):762–71. doi:10.7326/0003-4819-155-11-201112060-00375. - DOI - PubMed
    1. Final Recommendation Statement: Prostate Cancer: Screening—US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/Page/Document/Recommendatio.... Accessed December 15, 2014.
    1. Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am 2014;41(2):315–26. doi:10.1016/j.ucl.2014.01.007. - DOI - PMC - PubMed
    1. Da Rosa MR, Milot L, Sugar L, et al. A prospective comparison of MRI-US fused targeted biopsy versus systemic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging 2014. doi:10.1002/jmri.24710. - DOI - PubMed

    2. Prospective trial evaluating the ability of fusion biopsy to detect clinically significant diease and the predictive value of MRI utilizing established thresholds of Gleason ≥7, and Gleason 6 >50%.

    1. Fradet V, Kurhanewicz J, Cowan JE, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010;256(1):176–83. doi:10.1148/radiol.10091147. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources